Drugs for Allergic Disorders | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

129

May 1, 2013

View Complete Issue Table of Contents 2019

Drugs for Allergic Disorders

Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.

Drugs for Allergic Disorders

May 1, 2013 (Issue: 129)

Superseded by The Medical Letter "Drugs for Allergic Rhinitis and Allergic Conjunctivitis" - Issue 1622, April 19, 2021

The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.

Show References Hide References

1. AN Greiner et al. Allergic rhinitis. Lancet 2011; 378:2112.

2. JL Brozek et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126:466.

3. FE Simons and KJ Simons. Histamine and H₁-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128:1139.

4. FC Hoyte and RK Katial. Antihistamine therapy in allergic rhinitis. Immunol Allergy Clin North Am 2011; 31:509.

5. MA Kaliner et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2011; 106:S6.

6. Azelastine/fluticasone propionate (Dymista) for seasonal allergic rhinitis. Med Lett Drugs Ther 2012; 54:85.

7. W Carr et al. Anovel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012; 129:1282.

8. MK Church et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010; 65:459.

9. Y Katayose et al. Carryover effect on next-day sleepiness and psychomotor performance of nighttime administered antihistaminic drugs: a randomized controlled trial. Hum Psychopharmacol 2012; 27:428.

10. GS Richardson et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22:511.

11. G Scadding et al. Audit of nasal steroid use and effectiveness in a rhinitis clinic. Expert Rev Pharmacoecon Outcomes Res 2010; 10:87.

12. J Bergmann et al. The relationship of intranasal steroids to intraocular pressure. Curr Allergy Asthma Rep 2009; 9:311.

13. FM Baroody et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2011; 127:927.

14. TB Casale et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956.

15. L Cox et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011; 128:210.

16. W Busse et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129:983.

17. B Brinkhaus et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med 2013; 158:225.

18. AF Dumitru et al. Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. J Allergy Clin Immunol 2011; 127:1515.

19. M So et al. Safety of antihistamines during pregnancy and lactation. Can Fam Physician 2010; 56:427.

20. M Shimura et al. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. Am J Ophthalmol 2011; 151:697.

21. Alcaftadine (Lastacaft) for allergic conjunctivitis. Med Lett Drugs Ther 2011; 53:19.

22. L Gong et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther 2012; 34:1259.

23. RK Rajpal et al. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review. J Ocul Pharmacol Ther 2011; 27:305.

24. C Traidl-Hoffmann et al. Therapeutic management of atopic eczema. Curr Drug Metab 2010; 11:234.

25. A Wollenberg and LM Ehmann. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012; 24:253.

26. L Schneider et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.

27. FJ Bath-Hextall et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol 2010; 163:12.

28. DW Miller et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011; 10:531.

29. S Tintle et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011; 128:583.

30. F Pfab et al. Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis: a patient- and examiner-blinded, randomized, placebo-controlled, crossover trial. Allergy 2012; 67:566.

31. T Zuberbier et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.

32. M Staevska et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125:676.

33. K Weller et al. H₁-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects—a retrospective survey study. PLoS One 2011;6:e23931.

34. AP Kaplan. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol 2009; 123:713.

35. SM Hollander et al. Factors that predict the success of cyclosporine treatment for chronic urticaria. Ann Allergy Asthma Immunol 2011; 107:523.

36. Z Fedorowicz et al. Histamine H₂-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012; 3:CD008596.

37. M Maurer et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924.

38. FE Simons et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4:13.

39. JA Boyce et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. J Allergy Clin Immunol 2010; 126:1105.

40. In brief: Auvi-Q, a new epinephrine auto-injector. Med Lett Drugs Ther 2013; 55:13.

41. L Noimark et al. The use of adrenaline autoinjectors by children and teenagers. Clin Exp Allergy 2012; 42:284.

42. FE Simons et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010;125:419.

43. ES Edwards et al. Epinephrine 0.3 mg bioavailability following a single injection with a novel epinephrine auto-injector, e-cue, in healthy adults, with reference to a single injection using EpiPen 0.3 mg. J Allergy Clin Immunol 2012;129:AB179.

44. ES Edwards et al. Design validation and label comprehension study for a new epinephrine autoinjector. Ann Allergy Asthma Immunol 2013; 110:189.

45. A Karppinen et al. Levocetirizine for treatment of immediate and delayed mosquito bite reactions. Acta Derm Venereol (Stockh) 2006; 86:329.

46. L Cox et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl):S1.

47. DB Golden et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.

48. SY Lin et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013; 309:1278.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.